Dr. Daniel J. Burge is Senior Vice President, Clinical Development of Evommune. Dan joins Evommune from a consulting practice where he provided strategic advice and tactical implementation for clinical development of small molecules and biologics for biotechnology and pharmaceutical companies. Previously, Dan worked at Dermira as Senior Vice President of Clinical Development, participating in the in-licensing and development of lebrikizumab in atopic dermatitis prior to its acquisition by Eli Lilly, and as Vice President, Head of Cimzia® Strategy, leading the Phase 3 development and BLA submission for plaque psoriasis in collaboration with UCB. Prior to Dermira, Dan served as Senior Advisor at Gilead Sciences and was the Chief Medical Officer for Trubion Pharmaceuticals. Dan started his career in drug development at Immunex where he worked on the development of Enbrel®. Dan was promoted to Vice President where he was the therapeutic area Head for inflammatory diseases and was a leader on the Enbrel® Franchise Team. After Immunex’s acquisition by Amgen in 2002, Dan continued as Vice President and therapeutic area Head for Inflammatory disorders and co-leader of the Enbrel® Franchise Team at Amgen, as well as the Seattle site development Head.
Dan received his MD from Jefferson Medical College and completed his Internal Medicine residency at the Medical Center of Delaware and rheumatology fellowship at Hahnemann University where he also served as Clinical Instructor in Internal Medicine. After completing his fellowship, Dan was in clinical practice for six years where he also served as a clinical instructor to medical students and residents.